Graham Price, has 15 years experience in clinical development. He is curently Director of Clinical Pharmacology in Global Early Development at UCB, working in the areas of Immunology and Neurology. Most recently he was Chief medical Officer at Oxford BioMedica Ltd, responsible for all medical and clinical research activities leading the clinical development group and accountable for
Graham Price, has 15 years experience in clinical development. He is curently Director of Clinical Pharmacology in Global Early Development at UCB, working in the areas of Immunology and Neurology. Most recently he was Chief medical Officer at Oxford BioMedica Ltd, responsible for all medical and clinical research activities leading the clinical development group and accountable for global product development.
Prior to this position he was Vice President, Clinical Development for MedImmune Ltd in Cambridge UK, where he was accountable for product development in Europe and Vice President, Clinical Development at Takeda Global R&D where he was global clinical lead for cardiovascular and metabolic products.
In addition to extensive R&D experience he has experience of successful management of people, global portfolio management, global product development, clinical projects and alliance management. He has worked in a variety of therapeutic areas including hypertension, heart failure, diabetes, diabetic retinopathy, migraine, immunology, neurology, ophthalmology, oncology, anticoagulation and atherosclerosis. He has experience of clinical programs for small molecules, large molecules, immunotherapy and gene therapy.
He has a bachelor’s degree in neuroscience and bachelor’s degrees in Medicine and Surgery from Imperial College of Science Technology and Medicine, London. He is a fellow of the Faculty of Pharmaceutical Medicine .
He is a Fellow of the Royal Society of Medicine and has published on various topics including Alzheimer’s disease, hypertension, dyslipidaemia, ocular gene therapy and treatment of cervical malignancy.
Director, Clinical Pharmacology @ Focusing on clinical pharmacology activities in both Autoimmune Inflammatory Disease (AIID) and CNS pipeline, in order to drive further Early Clinical Development within UCB. Ensuring high quality input to Project Lifecycle Teams as well as safeguarding that the clinical pharmacology component of global clinical development programs for AIID/CNS projects are of high quality, meet regulatory standards and are delivered according to agreed timings. In close cooperation with Therapeutic Area Clinical Strategy, Modelling and Simulation and Clinical Research, implement the use of early, exploratory clinical studies to earlier demonstrate “Proof of Concept/Proof of Mechanism” and explore potential indications, maximising the value of UCB development candidates. From April 2012 to Present (3 years 9 months) Head of Clinical Delivery @ From 2014 to 2014 (less than a year) Consultant Pharmaceutical Medicine @ Currently Consulting at UCB Pharma UK
Interim Director of Clinical Strategy, Immunology From October 2011 to April 2012 (7 months) VP Clinical Development @ Led the EU Clinical development team From December 2008 to January 2010 (1 year 2 months) VP Clinical Sciences @ Therapeutic Area Head (EU) for the Cardiovascular area, immediately reporting to the Takeda board and globally accountable for strategic clinical development, evaluation of in-licensing opportunities, portfolio management and formulating strategic business plans to bring drugs to market and manage their life cycle. Responsible for a department of 4 medics, 5 scientists and support staff in EU and an extended team of 40 spread over US and Japan.
Key achievements in post
Completion and MAA/NDA submission of a fixed dose combination program for a line extension in the indication of hypertension.
Completion of a 7000 patient program for the prevention and treatment of retinopathy in type 1 and treatment of retinopathy in type 2 diabetes.
Completion of Phase III development of a lipid-lowering agent.
Establishment of a highly effective transatlantic cardiovascular development department through recruitment of staff in US.
Lead Development Division member to corporate restructuring initiative to accommodate new mergers and acquisitions and to respond to the changing internal and external environment of the Takeda business. From August 1998 to November 2008 (10 years 4 months) London, United KingdomMedical Project Leader. @ Experience and input into phase II to IV Clinical Trials across a variety of therapeutic areas including hypertension, diabetes, cardiac failure, obesity and vascular disease. Other duties included monitoring study centres in UK, clinical drug safety monitoring and reporting to MHRA, advisory board and opinion leader development and consultation, publications planning and strategic communication initiatives and clinical training and presentations (in house and to medical representatives). From August 1996 to August 1998 (2 years 1 month)
MBBS, General Medicine @ Imperial College London From 1985 to 1991 Imperial College London Graham Price is skilled in: Clinical Development, Clinical Research, Strategy Development, Clinical, Biotechnology, Clinical Trials, Therapeutic areas, Hypertension, Immunology, Internal Medicine, R&D, Clinical Trial Management, Diabetes, Clinical Pharmacology, Pharmacovigilance
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension